Bal Pharma Limited BALPHARMA NSEPHARMA

Q: What is the current share price of Bal Pharma Limited (BALPHARMA)?

As of 2026-07-15 09:52 IST, Bal Pharma Limited (BALPHARMA) trades at ₹89.50 on NSE. Its 52-week range is ₹60.42 to ₹99.16.

Q: What is the market capitalisation of BALPHARMA?

Bal Pharma Limited (BALPHARMA) has a market capitalisation of ₹142.49 Cr on NSE.

Q: What is the P/E ratio of BALPHARMA?

BALPHARMA trades at a trailing price-to-earnings (P/E) ratio of 19.63. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.53.

Q: Does BALPHARMA pay a dividend?

Bal Pharma Limited (BALPHARMA) currently offers a dividend yield of 1.51%.

Q: What is the return on equity (ROE) of BALPHARMA?

BALPHARMA has a return on equity (ROE) of 7.64%. Its return on capital employed (ROCE) is 18.01%.

Q: Is BALPHARMA a good stock to buy?

This page provides a data-driven analysis of Bal Pharma Limited (BALPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.balpharma.com

Company Profile ↓

₹89.50

-9.74% 1Y

Mkt Cap₹142.49 Cr

P/E19.63

P/B1.53

Div. Yield1.51%

52W High₹99.16

52W Low₹60.42

Book Value₹51.65

EPS (TTM)₹4.56

Company Overview

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 18.0%.

Consistent Profit Growth

Net profit has compounded at 34.7% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 19.6, below the sector median of 40.0.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹311.66 Cr (+2.8% YoY); net profit ₹6.28 Cr.
Trailing 12 Months Year-on-year growth — revenue +2.8%, earnings -12.9%.
5-Year Trend Long-term compounding — revenue CAGR 1.1%, profit CAGR 34.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	1.09%
1 Year:	2.83%

Compounded Profit Growth

5 Years:	34.69%
1 Year:	-12.91%

Stock Price Performance

1 Year:	-9.74%
6 Months:	+21.75%
3 Months:	+16.90%
1 Month:	+1.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 75% of range

₹60.42 ₹99.16

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)63.81 · Neutral

Price Performance

1M+1.96%

3M+16.90%

6M+21.75%

1Y-9.74%

Valuation vs Sector

P/E of 19.63 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 34.7% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

19.63

Industry PE

39.97

Forward P/E est.

22.54

PEG Ratio

Book Value

₹51.65

Price to Book

1.53

P/S

0.40

EV/EBITDA

8.84

Dividend Yield

1.51%

Growth (CAGR)

Revenue 5Y

1.09%

Profit 5Y

34.69%

Revenue (YoY)

2.83%

Earnings (YoY)

-12.91%

Profitability & Returns

ROCE

18.01%

ROE

7.64%

ROA

1.67%

Profit Margin

2.02%

Op Margin

6.68%

Gross Margin

49.32%

EPS (Latest Qtr)

₹2.26

EPS (TTM)

₹4.56

Balance Sheet & Liquidity

Debt/Equity

1.94

Quick Ratio

0.59

Current Ratio

1.05

Debt

₹159.52 Cr

Total Assets

₹375.54 Cr

Current Assets

₹262.23 Cr

Working Capital

₹13.01 Cr

Ownership

Promoter Holding

65.53%

Chg in Prom Hold

14.66%

FII / Inst Holding

0.00%

Chg in FII Hold

-0.14%

Financial Snapshot

Enterprise Value

₹142.49 Cr

Total Revenue (TTM)

₹311.66 Cr

EBITDA

₹33.83 Cr

Free Cash Flow

₹8.06 Cr

Operating Cash Flow

₹30.44 Cr

Shares Outstanding

₹1.59 Cr

Gross Margin

49.32%

Payout Ratio

30.38%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BALPHARMA Bal Pharma Limited NSEPHARMA	89.50	19.63	₹142.49 Cr	1.51%	18.01%	7.64%	1.09%	34.69%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,948.80	40.77	₹4.68 L Cr	0.83%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	7,315.50	75.61	₹1.94 L Cr	0.44%	18.96%	15.32%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,952.20	87.70	₹1.68 L Cr	0.78%	9.05%	25.79%	13.27%	20.22%
5	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,981.00	66.51	₹1.29 L Cr	0.23%	19.79%	20.48%	15.33%	33.34%
6	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,440.10	22.07	₹1.16 L Cr	0.90%	14.86%	11.27%	7.23%	11.45%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,137.40	22.71	₹1.14 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,494.30	21.42	₹1.14 L Cr	0.72%	28.42%	23.76%	19.10%	131.46%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	1,099.00	99.82	₹1.07 L Cr	0.18%	12.57%	13.42%	22.37%	9.34%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	82.45 Cr	70.39 Cr	92.54 Cr	81.66 Cr	94.63 Cr	74.36 Cr	73.69 Cr	-	81.88 Cr	65.87 Cr	74.02 Cr	87.69 Cr	84.08 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	43.97 Cr	33.54 Cr	39.94 Cr	46.16 Cr	38.33 Cr
Gross Profit	-	-	-	-	-	-	-	-	37.90 Cr	32.33 Cr	34.09 Cr	41.53 Cr	45.75 Cr
Operating Expenses	74.29 Cr	63.95 Cr	84.84 Cr	73.87 Cr	85.03 Cr	67.89 Cr	66.00 Cr	-	32.44 Cr	28.79 Cr	30.63 Cr	35.21 Cr	38.24 Cr
Operating Income	6.07 Cr	3.91 Cr	5.28 Cr	4.83 Cr	7.44 Cr	4.04 Cr	5.21 Cr	-	5.46 Cr	3.54 Cr	3.46 Cr	6.32 Cr	7.51 Cr
EBITDA	8.16 Cr	6.44 Cr	7.70 Cr	7.79 Cr	9.60 Cr	6.47 Cr	7.69 Cr	-	8.72 Cr	6.78 Cr	6.85 Cr	9.87 Cr	10.33 Cr
Interest Expense	3.85 Cr	3.64 Cr	3.82 Cr	3.66 Cr	4.14 Cr	4.24 Cr	3.65 Cr	-	3.95 Cr	4.05 Cr	3.86 Cr	4.85 Cr	4.06 Cr
Pretax Income	2.41 Cr	43.00 L	1.60 Cr	1.27 Cr	5.75 Cr	62.00 L	1.36 Cr	-	2.59 Cr	20.85 L	71.73 L	1.79 Cr	3.22 Cr
Tax Provision	79.00 L	34.00 L	63.01 L	42.00 L	20.99 L	36.00 L	32.00 L	-	-2.83 Cr	0	0	0	-38.62 L
Net Income	1.62 Cr	9.00 L	97.00 L	85.00 L	5.53 Cr	26.00 L	1.04 Cr	-	5.43 Cr	20.06 L	70.95 L	1.78 Cr	3.59 Cr
Diluted EPS	1.02	0.05	0.61	0.56	3.46	0.16	0.65	-	3.40	0.13	0.45	1.12	2.26

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	187.00 Cr	198.00 Cr	229.00 Cr	211.00 Cr	225.00 Cr	171.00 Cr	251.00 Cr	-	301.71 Cr	326.35 Cr	303.08 Cr	311.66 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	176.24 Cr	195.19 Cr	157.89 Cr	157.97 Cr
Gross Profit	-	-	-	-	-	-	-	-	125.46 Cr	131.16 Cr	145.19 Cr	153.70 Cr
Operating Expenses	170.00 Cr	183.00 Cr	214.00 Cr	194.00 Cr	207.00 Cr	166.00 Cr	226.00 Cr	-	107.92 Cr	109.38 Cr	125.40 Cr	132.87 Cr
Operating Income	10.00 Cr	8.00 Cr	9.00 Cr	10.00 Cr	12.00 Cr	-3.00 Cr	15.00 Cr	-	17.55 Cr	21.77 Cr	19.79 Cr	20.82 Cr
EBITDA	17.00 Cr	15.00 Cr	15.00 Cr	17.00 Cr	18.00 Cr	5.00 Cr	25.00 Cr	-	24.37 Cr	32.02 Cr	31.76 Cr	33.83 Cr
Interest Expense	7.00 Cr	6.00 Cr	8.00 Cr	9.00 Cr	13.00 Cr	13.00 Cr	12.00 Cr	-	10.50 Cr	12.90 Cr	16.85 Cr	16.82 Cr
Pretax Income	5.00 Cr	3.00 Cr	3.00 Cr	3.00 Cr	-0	-14.00 Cr	4.00 Cr	-	4.75 Cr	9.05 Cr	5.14 Cr	5.93 Cr
Tax Provision	1.25 Cr	2.70 Cr	3.42 Cr	2.61 Cr	0	70.00 L	-60.00 L	-	2.13 Cr	1.60 Cr	-2.10 Cr	-38.62 L
Net Income	4.00 Cr	1.00 Cr	-0	0	2.00 Cr	-13.00 Cr	5.00 Cr	-	2.57 Cr	7.39 Cr	7.22 Cr	6.28 Cr
Diluted EPS	2.82	1.10	1.24	1.96	2.67	-8.62	3.20	3.79	1.67	4.96	4.56	-

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	164.00 Cr	211.00 Cr	233.00 Cr	260.00 Cr	261.00 Cr	238.00 Cr	240.00 Cr	-	313.17 Cr	319.84 Cr	335.69 Cr	375.54 Cr
Current Assets	-	-	-	-	-	-	-	-	228.16 Cr	234.16 Cr	234.87 Cr	262.23 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	1.49 Cr	4.20 Cr	1.75 Cr	2.30 Cr
Inventory	-	-	-	-	-	-	-	-	98.00 Cr	87.81 Cr	103.02 Cr	116.36 Cr
Receivables	-	-	-	-	-	-	-	-	93.98 Cr	99.62 Cr	92.44 Cr	93.63 Cr
Total Liabilities	-	-	-	-	-	-	-	-	249.47 Cr	247.87 Cr	258.29 Cr	293.29 Cr
Current Liabilities	-	-	-	-	-	-	-	-	209.33 Cr	203.06 Cr	219.50 Cr	249.23 Cr
Long Term Debt	-	-	-	-	-	-	-	-	30.52 Cr	36.35 Cr	31.40 Cr	31.88 Cr
Total Debt	49.00 Cr	89.00 Cr	93.00 Cr	110.00 Cr	124.00 Cr	118.00 Cr	110.00 Cr	-	133.08 Cr	142.25 Cr	152.31 Cr	159.52 Cr
Total Equity	55.00 Cr	55.00 Cr	62.00 Cr	65.00 Cr	66.00 Cr	52.00 Cr	54.00 Cr	-	63.79 Cr	72.00 Cr	77.42 Cr	82.23 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	1.57 Cr	1.58 Cr	1.59 Cr	1.59 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	15.00 Cr	-19.00 Cr	6.00 Cr	1.00 Cr	8.00 Cr	23.00 Cr	22.00 Cr	-	-1.54 Cr	22.81 Cr	20.32 Cr	30.44 Cr
Investing Cash Flow	-5.00 Cr	-14.00 Cr	-8.00 Cr	-4.00 Cr	-8.00 Cr	-5.00 Cr	-6.00 Cr	-	-22.18 Cr	-18.89 Cr	-14.92 Cr	-20.70 Cr
Financing Cash Flow	-7.00 Cr	32.00 Cr	-6.00 Cr	4.00 Cr	0	-20.00 Cr	-17.00 Cr	-	24.09 Cr	-1.21 Cr	-7.84 Cr	-9.59 Cr
Capital Expenditure	-6.00 Cr	-15.00 Cr	-8.00 Cr	-4.00 Cr	-9.00 Cr	-5.00 Cr	-3.00 Cr	-	-14.65 Cr	-10.98 Cr	-18.79 Cr	-22.38 Cr
Free Cash Flow	9.00 Cr	-34.00 Cr	-2.00 Cr	-3.00 Cr	-1.00 Cr	18.00 Cr	19.00 Cr	-	-16.18 Cr	11.83 Cr	1.53 Cr	8.06 Cr
Net Change in Cash	2.00 Cr	-1.00 Cr	-8.00 Cr	1.00 Cr	-0	-2.00 Cr	0	-	37.43 L	2.71 Cr	-2.44 Cr	15.71 L

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	41.6%	40.2%	47.9%	49.3%
Operating Margin %	5.3%	4.0%	3.9%	4.7%	5.3%	-1.8%	6.0%	-	5.8%	6.7%	6.5%	6.7%
Net Margin %	2.1%	0.5%	-0.0%	0.0%	0.9%	-7.6%	2.0%	-	0.9%	2.3%	2.4%	2.0%
ROE %	7.3%	1.8%	-0.0%	0.0%	3.0%	-25.0%	9.3%	-	4.0%	10.3%	9.3%	7.6%
ROCE %	-	-	-	-	-	-	-	-	16.9%	18.6%	17.0%	16.5%

Shareholding Pattern

Insiders

65.53%

Institutions

0.00%

Public Float

0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BALPHARMA

Google News ue, 12 May 2026

With EPS Growth And More, Bal Pharma (NSE:BALPHARMA) Makes An Interesting Case - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQMjFYNXpLY3dRcmFNeHdWVUdSbGI5UTBueEpFV09CbXNNRVBtcll3ckZHMGxEb2RRWWp2T1pPVE9fVVVHY3o1bUdXT1lFYU9xY0FWMG95Q1NVYmMxVFVyc0FGelJkT0U5QTFJQ3ZpeklqZF96UE03VHRDNWkxejRpaDJmbWotTWxoN0x0TW…

Google News hu, 09 Jul 2026

Bal Pharma seeks approval to issue warrants to promoter - scanx.trade

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPSjJPeHM0YWlZTWVjZzMzRHZwYmhHbzVZQU5hdXcwZUVvaGRVWERGUzBtdXY2SFBrMnlwa0tGQXlRaDVtNXdZcmxzeXNyTFpxT1p2V0UycmZuek96Z2Jva29JUnpBNmFhNXdnVExrNVZFbTRubmFHOThtQmlOOGt6VGdndVhKelRVck1ka0…

Google News Sat, 03 Jan 2026

Bal Pharma Ltd. Share Price Today - Bal Pharma Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE9NbWJBRllIVWF4YTd2alVncHJaM1Z2VHozMzdYMnVjWWN6TkVGNU9yQmZoc0R1Z2VFOTlDTUNWd1kxeE9mXzk2Nnl6a0lpcFdZeVMtdUc0Z0IxSEZpcy1ER2RvZmxPbW5SNUdZSU5HenQ2SGxRV01RcW1ySQ?oc=5" target="_blank">B…

Google News hu, 28 May 2026

Bal Pharma Consolidated March 2026 Net Sales at Rs 84.08 crore, up 2.69% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxORlpoNmt6UlNPdE5XbmZzd1pJeTVaSmp6NzhPSXp3Y2dNTzlCTGVxQUxNWUZmZVlxemRzc1pXUm9UTUlUTjlFNWt6WHVQc2NmcWx1OERMR3c3UnZ6TFppVUVkM2Zyb3UzekVXZUZTY19aRVN2TEpxbHVHcDRtYWF2UUFWWm8xeFNnQ2ozRW…

Google News Fri, 19 Sep 2025

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Bal Pharma Limited's (NSE:BALPHARMA) CEO For Now - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOeFdCaTk5MjcyOWRHdExDLXhrTGI4Y2RHMjhhTW1pcUY3MWNmQVE3VmNIVkxJd2gxRlZ1RG5HZ1czQkVtdmZ3aThQNlNzLVRwMzFTQnQ4YS1HbnZUOGtUUDZ3N2tpd0ZwOXhVM0pKYXB0cEM0LXRIUnhKQmNDeXZSRUI4aHdkYUJicXg5RT…

Google News Fri, 29 May 2026

Bal Pharma FY26 net profit falls 13.4%, announces dividend - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNWk1FUWM5M3BBOGllRVpiUG1rMlFveENhOGwwWUcwakpmQ2JaOUxGTmx1X0lubG9nVUZ6OUEtT2FXV3FuUjFiWW5WRjF5MURueFl2VmQ5b01lNkpnSUFVUjEzWTdFN3J0X3NPSFZabGdjSTAxdjJSb0QzOGpHV3lwVUFoSmx2M25TaVlfQ0…

BALPHARMA — Frequently Asked Questions

What is the current share price of Bal Pharma Limited (BALPHARMA)?

As of 2026-07-15 09:52 IST, Bal Pharma Limited (BALPHARMA) trades at ₹89.50 on NSE. Its 52-week range is ₹60.42 to ₹99.16.

What is the market capitalisation of BALPHARMA?

Bal Pharma Limited (BALPHARMA) has a market capitalisation of ₹142.49 Cr on NSE.

What is the P/E ratio of BALPHARMA?

BALPHARMA trades at a trailing price-to-earnings (P/E) ratio of 19.63. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.53.

Does BALPHARMA pay a dividend?

Bal Pharma Limited (BALPHARMA) currently offers a dividend yield of 1.51%.

What is the return on equity (ROE) of BALPHARMA?

BALPHARMA has a return on equity (ROE) of 7.64%. Its return on capital employed (ROCE) is 18.01%.

Is BALPHARMA a good stock to buy?

This page provides a data-driven analysis of Bal Pharma Limited (BALPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Bal Pharma Limited BALPHARMA NSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

With EPS Growth And More, Bal Pharma (NSE:BALPHARMA) Makes An Interesting Case - simplywall.st

Bal Pharma seeks approval to issue warrants to promoter - scanx.trade

Bal Pharma Ltd. Share Price Today - Bal Pharma Ltd. Stock Price Live NSE/BSE - CNBC TV18

Bal Pharma Consolidated March 2026 Net Sales at Rs 84.08 crore, up 2.69% Y-o-Y - Moneycontrol.com

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Bal Pharma Limited's (NSE:BALPHARMA) CEO For Now - simplywall.st

Bal Pharma FY26 net profit falls 13.4%, announces dividend - scanx.trade

BALPHARMA — Frequently Asked Questions

What is the current share price of Bal Pharma Limited (BALPHARMA)?

What is the market capitalisation of BALPHARMA?

What is the P/E ratio of BALPHARMA?

Does BALPHARMA pay a dividend?

What is the return on equity (ROE) of BALPHARMA?

Is BALPHARMA a good stock to buy?

Explore More